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INTRODUCTION
Medically harmful substance use is com-
mon in the United States (U.S.), with
an estimated 24.6 million Americans aged
12 years and older having used illicit drugs
or engaged in non-medical drug use in
the prior month, representing 9.4% of the
population aged 12 years or older (1). Mar-
ijuana is the most commonly used illicit
drug. In 2013, there were 19.8 million cur-
rent users aged 12 years or older, 7.5%
of the population in this age group (1).
However, in 2013, only 2.5 million indi-
viduals in the U.S. received treatment at
a specialty facility for an illicit drug or
alcohol use problem in the past year, sim-
ilar to numbers from 2002 through 2012
(1). Therefore, the vast majority of per-
sons with substance use disorders (SUD)
are not seen by specialty programs, and
efforts to integrate SUD care with pri-
mary care in general medical settings
have largely fallen short. Drug use dis-
orders produce a wide variety of med-
ical problems and are important contrib-
utors to years of life lost due to dis-
ability (2). A common barrier to treat-
ing individuals with cannabis use disor-
ders (CUD) and other SUD in medical
settings or successfully linking them to
indicated follow-up care is inability of
clinicians to engage patients in a collab-
orative dialog concerning the medically
harmful consequences of unhealthy sub-
stance use and evidence-based treatment
options aligned with patient values. Clin-
icians often do not use a shared-decision-
making approach to discuss with patients’
different options for care personalized to
risk categories and their preferences (3).
Indeed, patients are often offered a single
or narrow set of options for follow-up
care, compromising their motivation to
change their medically harmful substance
use as well as engagement and initiation of
treatment.
Here, I illuminate a need for systematic
research in medical settings to evaluate a
patient-centered model for treating CUD
and other SUD, which incorporates prin-
ciples of shared-decision-making engag-
ing both patients and clinicians, grounded
in personalized-medicine tailored to sub-
stance use risk categories and individu-
alized patient values/preferences. Shared-
decision-making and patient-centered care
(4), considering individual preferences for
treatment options, are critical for patient
engagement in substance use disorder care.
They necessitate a collaborative dialog
between patients and providers in which
they discuss benefits and risks of differ-
ent evidence-based treatments, as well as
the importance of patients in making deci-
sions about their care. The provider helps
patients understand their medical condi-
tion in a manner in which they feel empow-
ered to make decisions about options for
evidence-based care aligned with their val-
ues, in the spirit of personalized medicine
(5). Medical setting providers need to eval-
uate: (1) substance use disorder severity,
(2) presence of co-occurring psychiatric
and other medical conditions, (3) readi-
ness of patients to change their medically
harmful substance use, (4) reasons for this
readiness or hesitancy to do so, and (5)
how they may help patients in institut-
ing an action plan consistent with their
preferences (5).
Rigorous research is needed in general
medical settings testing effectiveness
of primary and secondary prevention
interventions incorporating principles
of shared-decision-making and patient-
centered care for individuals with multiple
SUD (marijuana, alcohol, tobacco, or
other commonly abused substances). This
research is particularly needed in ado-
lescents and young adults (age range
12–25 years old), where abuse of mari-
juana and prescription drugs has escalated
in recent years (1). Important features
of primary and secondary prevention
interventions to be tested are: (1) be sim-
ple so they could be routinely delivered
by clinicians at medical settings with-
out cumbersome training and fidelity
requirements, (2) utilize health infor-
mation technology together with clinical
decision support (CDS) tools to extend
role of clinicians and simplify care deliv-
ery, (3) be either integrated with or utilize
health information collected from elec-
tronic health records (EHRs), (4) use
validated and brief electronic screening
and brief assessment tool(s) for identify-
ing risk categories of commonly abused
substances, in a comprehensive way, (5)
be sustainable and easily disseminated at
conclusion of trials to applicable med-
ical settings and stakeholders, (6) explain
means of scalability and sustainability
of effective secondary preventions, (7)
include cost-effectiveness or other relevant
cost–benefit analyses.
THE ASPIRE FRAMEWORK FOR
PATIENT-CENTERED TREATMENT
RESEARCH
Recognizing a spectrum of neurobiological
components for cannabis and other SUD,
below I propose the ASPIRE model for
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patient-centered treatment, which uses as
its foundational principle shared-decision-
making to tailor personalized medical care
to particular risk categories and problems
that individual patients report as most
distressing to their daily lives. “A” refers
to anhedonia/reward-deficit and “S” to
a stressful state, concerning a sensitized
brain anhedonia and stress system follow-
ing repeated heavy drug use and during
drug withdrawal. According to prominent
addictive-disorder researcher George Koob
and over 30 years of cumulative neuro-
science research by his team and others,
this sensitized brain system that produces
a negative emotional state in which moti-
vation to remove it drives continued drug-
taking behavior (6). This is analogous to
Koob’s view of a “reward-deficit/stress sur-
feit” component of SUD in which “the neg-
ative emotional state is . . . mediated not
only by deficits in the brain systems that
mediate positive reinforcement but also
by recruitment of brain stress/dysphoria
systems that mediate negative reinforce-
ment” (6). “P” refers to pathological lack of
self-control to cut down drug use despite
undesirable consequences. The compul-
sive drug use is hypothesized to involve
impaired cortical regulation of impulses to
reduce drug-taking despite negative impli-
cations (6). Neuroscience research over
the past 25 years suggests that this lack
of self-control is primed by a hypersensi-
tive memory-trace of the reinforcing drug
experience, which subconsciously drives
compulsive drug seeking when coming
in contact with drug-associated contexts
(6). “I” and “R” refer to insomnia and
restlessness, which are common cannabis
withdrawal symptoms following repeated
heavy drug use (7–9). Indeed, insomnia
and restlessness are often rated by indi-
viduals with cannabis dependence as dis-
tressing and persistent withdrawal symp-
toms, which increase likelihood of relapse
and hinder quit attempts (7–9). “E” refers
to excessive and compulsive preoccupation
with seeking drug reinforcers compared
with natural reinforcers after transition
from volitional to compulsive drug use,
particularly following drug craving when
an individual with a substance use disorder
comes in contact with a drug-associated
environment (6). In summary, system-
atic research is needed to test effectiveness
of shared-decision-making and patient-
centered care according to patients’ risk
categories and reporting of role of com-
ponents in the ASPIRE framework to their
overall functioning and motivation for
continued drug use. I include discussion
of CUD as an illustrative example. How-
ever, the ASPIRE model is generalizable
to patient-centered care for other SUD,
too. For instance, insomnia and restless-
ness are common withdrawal symptoms
for other SUDs such as nicotine, alcohol,
opioid, and cocaine use disorders, which
patients often find particularly distress-
ing to their overall functioning and daily
lives (10–13). In addition, the A, S, P,
and E components are fundamental to the
neurobiology of other SUDs (6, 14–16).
Thus, across SUDs, it would be helpful for
clinicians to ascertain these components’
role in a patient’s overall health and well-
being, tailoring treatments according to the
shared-decision-making model. Clinicians
could then collaboratively and transpar-
ently engage their patients in instituting
personalized action plans on how to best
address them, weighing different evidence-
based treatment options according to their
clients’ preferences.
Furthermore, for patients at the high-
severity end of the SUD spectrum, clini-
cal research is needed testing effectiveness
of combined behavioral and pharmaco-
logical interventions targeting prominent
components in the ASPIRE framework.
For CUD, evidence-based behavioral inter-
ventions include motivational enhance-
ment therapy, cognitive–behavioral ther-
apy, community-reinforcement approach,
contingency management, and behavioral
therapies aimed for adolescents (17). Phar-
macological agents showing promise in
proof-of-concept clinical research by Mar-
garet Haney’s and Barbara Mason’s teams
(18–20), meriting randomized controlled
trials testing their effectiveness in treatment
seekers, include: (1) noradrenergic alpha-
2 receptor agonists (such as lofexidine or
guanfacine) together with delta-9 tetrahy-
drocannabinol (THC) replacement ther-
apy (such as nabilone) to reduce cannabis
use, sleep disturbances, restlessness, anhe-
donia, and other prominent cannabis with-
drawal symptoms, and (2) gabapentin for
decreasing cannabis use as well as persistent
cannabis withdrawal symptoms, such as
craving and mood and sleep disturbances.
In addition, the National Drug Abuse
Treatment Clinical Trials Network of the
National Institute on Drug Abuse (NIDA
CTN) is presently conducting a multi-
site clinical trial evaluating the efficacy
of N -acetylcysteine versus placebo, added
to contingency management, for cannabis
cessation in adults aged 18–50 years old.
The basis for this double-blind randomized
controlled trial is positive findings from a
randomized controlled trial in cannabis-
dependent youth, which found more than
twice greater odds of cannabis abstinence
during treatment with N -acetylcysteine
compared with placebo (21).
Since ASPIRE framework components
generalize to treatment for other drugs of
abuse, randomized clinical trials are also
needed evaluating efficacy of pharmaco-
logical agents targeting ASPIRE compo-
nents frequently reported to cause psy-
chological distress in treatment-seeking
patients. For instance, a recent randomized
clinical trial from Barbara Mason’s group
suggests that gabapentin treatment may be
efficacious in reducing sleep disturbances
and alcohol use and craving in alcohol-
dependent patients (22), and an additional
clinical trial is needed to replicate this.
Clinical research from various groups sug-
gests that noradrenergic alpha-2 recep-
tor agonists (clonidine, guanfacine, lofex-
idine) may be efficacious in reducing stress
and stress-induced craving for cocaine and
opioids (23–25), and randomized clini-
cal trials are needed to test whether these
agents could also enhance abstinence from
drug use in treatment seekers. In this
regard, the ASPIRE framework may be
useful to query patients prior to ran-
domization on whether they experience
individual components that these phar-
macologic interventions are postulated to
impact (e.g., stress, insomnia, restlessness).
If so, the likelihood of detecting an effi-
cacy signal may be improved by employ-
ing a personalized-medicine approach. In
other words, patient subgroups that may
benefit most from these agents would
be included in randomized trials, accord-
ing to the U.S. Food and Drug Admin-
istration’s (FDA’s) guidance on enrich-
ment strategies for clinical trials to support
approval of human drugs and biological
products (26).
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CONCLUSION
Recent U.S. healthcare reform legislation
provides unprecedented opportunities for
SUD treatment to be integrated into gen-
eral medical settings (27). This expan-
sion of health care use by patients with
SUD, under the 2010 Patient Protection
and Affordable Care Act (ACA) and 2008
Mental Health Parity and Addiction Equity
Act (MHPAEA), calls for new transfor-
mative research to guide evidence-based
practices for SUD care in medical set-
tings (27). Key research gaps need to be
addressed concerning how to most effec-
tively implement patient-centered person-
alized care incorporating shared-decision-
making to engage patients as advocates
in their treatment. The ASPIRE model
described herein calls for personalized-
medicine research on how to most effec-
tively tailor evidence-based interventions
in medical settings to address problem
categories, which patients report as dis-
tressing to their daily lives. Among these
may be core components of addictive
disorders described in this framework.
Clinical research programs, such as the
NIDA CTN, can serve an important
role in this endeavor. Leveraging exist-
ing health information system infrastruc-
tures in practice-based research networks
is needed to accelerate this line of research.
This could enable cost-efficient enroll-
ment of patients into trials, recruitment
of providers to deliver interventions within
research studies, and utilization of existing
health information technologies, including
EHRs, mobile-health/telemedicine tech-
nologies, and EHRs-linked patient reg-
istries, for efficient clinical data collection
to conduct low-cost-efficient effectiveness
research.
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